BACKGROUND AND AIMS: New lesions of @entity30 occur early after ileal or ileocolonic resection and ileocolonic @entity254 . We performed a double blind controlled trial to evaluate the safety and tolerance of recombinant @entity1 @entity688 ( @entity688 ; Tenovil) in subjects operated on for @entity30 . We also assessed the effect of Tenovil in preventing endoscopic recurrence 12 weeks after surgery. METHODS: @entity1 with @entity30 who underwent curative ileal or ileocolonic resection and primary @entity254 were randomised within two weeks after surgery to receive subcutaneous Tenovil 4 microg/kg once daily (QD) (n=22) or 8 microg/kg twice weekly (TIW) (n=21), or placebo (QD or TIW) (n=22). An ileocolonoscopy was performed after 12 weeks of treatment. RESULTS: Compliance was excellent. The most frequently observed adverse events were mild and moderate in severity and equally distributed across treatment groups. Thirty seven @entity1 in the pooled Tenovil group and 21 @entity1 in the pooled placebo group were evaluable by endoscopy. At 12 weeks, 11 of 21 @entity1 (52%) in the placebo group had recurrent lesions compared with 17 of 37 @entity1 (46%) in the Tenovil group (ns). The incidence of severe endoscopic recurrence was similar in both groups (9%). CONCLUSION: Tenovil treatment for 12 consecutive weeks in @entity1 with @entity30 after intestinal resection was safe and well tolerated. No evidence of prevention of endoscopic recurrence of @entity30 by Tenovil was observed.

@entity688 (Tenovil) in the prevention of postoperative recurrence of XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'human', 'patients'] @entity254 :: ('MESH:C563598', 'Disease') :: ['anastomosis'] @entity688 :: ('3586', 'Gene') :: ['IL-10', 'interleukin 10'] @entity30 :: ('MESH:D003424', 'Disease') :: ["Crohn's disease"]
@entity30 :: (MESH:D003424,Disease) :: ['Crohn's disease']
